SERMs for Men: Complete Guide to Clomid, Enclomiphene, Tamoxifen, and Raloxifene (2026)

What Are SERMs?

Selective estrogen receptor modulators, commonly abbreviated as SERMs, are a class of pharmacological compounds that interact with estrogen receptors throughout the body in a tissue-selective manner. Unlike aromatase inhibitors, which reduce circulating estrogen levels systemically, SERMs occupy estrogen receptor binding sites and exert either agonistic or antagonistic effects depending on the target tissue. This selectivity is what makes SERMs for men a subject of considerable clinical and research interest.

The concept of tissue selectivity is central to understanding SERM pharmacology. A given SERM may block estrogen signalling in one tissue, such as the hypothalamus, while simultaneously acting as a partial estrogen agonist in another, such as bone. This dual nature distinguishes SERMs from pure estrogen antagonists and from direct hormonal replacement. It also explains why different SERMs produce meaningfully different clinical outcomes despite sharing the same general mechanism of action.

In the context of male physiology, SERMs are relevant primarily because of their ability to modulate the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus uses estrogen as a key feedback signal to regulate gonadotropin production. When a SERM blocks estrogen receptor activity at the hypothalamus, the brain interprets this as low estrogen, a signal that triggers increased release of gonadotropin-releasing hormone (GnRH). This cascade ultimately results in elevated testosterone production from the testes, a process that occurs without suppressing spermatogenesis.

Four SERMs have accumulated the most clinical evidence and research attention for male applications: clomiphene citrate, enclomiphene citrate, tamoxifen, and raloxifene. Each occupies a distinct pharmacological niche. This pillar guide examines each compound in detail, compares their profiles, and contextualizes them within current research. Forthcoming articles in this series will provide deep dives into tamoxifen for men, enclomiphene for men, raloxifene for gynecomastia, and a complete post cycle therapy (PCT) guide.

How SERMs Raise Testosterone in Men

The HPG axis operates through a tightly regulated negative feedback loop. The hypothalamus secretes GnRH in a pulsatile fashion, which stimulates the anterior pituitary to release LH and FSH. LH acts on Leydig cells in the testes to drive testosterone synthesis, while FSH supports Sertoli cell function and spermatogenesis. Circulating testosterone is partially converted to estradiol (E2) by the aromatase enzyme, and this estradiol feeds back to the hypothalamus, suppressing further GnRH release. The system is designed to maintain hormonal homeostasis.

SERMs interrupt this feedback loop at a specific point. By occupying estrogen receptors in the hypothalamus (and, to a lesser extent, the pituitary), SERMs prevent circulating estradiol from exerting its normal inhibitory signal. The hypothalamus, effectively “blind” to estrogen, responds as though estrogen levels are low. It increases GnRH pulse frequency and amplitude, which in turn drives higher LH and FSH secretion from the pituitary. The elevated LH stimulates greater testosterone production from the Leydig cells (Katz et al., 2012).

This mechanism is fundamentally different from exogenous testosterone administration. When testosterone is supplied externally, as in testosterone replacement therapy (TRT), the hypothalamus detects supraphysiological or adequate androgen and estrogen levels and suppresses GnRH accordingly. This leads to reduced LH and FSH output, testicular atrophy, and impaired spermatogenesis. SERMs, by contrast, work with the body’s endogenous production machinery rather than replacing it. The testes remain active. Sperm production is maintained or even enhanced due to elevated FSH levels.

The magnitude of testosterone elevation varies by compound, dose, and baseline hormonal status. In hypogonadal men, clomiphene citrate has been shown to increase total testosterone levels from a mean of approximately 228 ng/dL to 612 ng/dL over several months of treatment (Guay et al., 2003). This represents a clinically significant improvement, though the degree of response is influenced by age, body composition, and the underlying cause of hypogonadism. Men with primary testicular failure (elevated LH, low testosterone) are less likely to respond than those with secondary hypogonadism, where the pituitary-gonadal signalling pathway remains intact.

The distinction between primary and secondary hypogonadism is critical when evaluating SERM candidacy. SERMs require functional testicular tissue capable of responding to increased LH stimulation. In cases where testicular function is severely compromised, the hypothalamic-pituitary signal may increase substantially without a proportional testosterone response.

Clomiphene Citrate (Clomid): The Most Studied SERM for Men

Clomiphene citrate remains the most extensively studied SERM for male hormonal modulation. Originally developed and FDA-approved for the treatment of anovulatory infertility in women, clomiphene has been used off-label in men for decades. It is a racemic mixture of two stereoisomers: enclomiphene (trans-clomiphene), which acts as an estrogen antagonist, and zuclomiphene (cis-clomiphene), which has weak estrogen agonist properties. The ratio of these isomers in commercial preparations is approximately 62% enclomiphene to 38% zuclomiphene.

The clinical evidence supporting clomiphene use in men is substantial. Katz et al. (2012) conducted a comparative analysis of clomiphene citrate versus testosterone gel in hypogonadal men, reporting that clomiphene produced statistically significant increases in total testosterone, free testosterone, and gonadotropin levels while preserving semen parameters. Guay et al. (2003) demonstrated that clomiphene increased free testosterone levels in men with both secondary hypogonadism and erectile dysfunction, with improvements in sexual function accompanying the hormonal changes.

Kim et al. (2012) positioned clomiphene citrate as a first-line consideration for the treatment of hypogonadism in men of reproductive age, noting that fertility preservation is a critical clinical parameter that exogenous testosterone fails to address. This perspective has gained increasing traction in endocrinology and urology literature, particularly as awareness grows regarding the fertility-suppressive effects of TRT in younger men.

The standard research dose of clomiphene citrate for men typically falls in the range of 25 to 50 mg daily, though some protocols employ every-other-day dosing to mitigate side effects. The compound has a long half-life, approximately five to seven days for the zuclomiphene isomer, which means steady-state levels accumulate over weeks. A detailed examination of clomiphene as a testosterone alternative is available in the companion article.

Clomiphene is not without limitations. The zuclomiphene isomer’s weak estrogenic activity has raised questions about whether it may partially counteract the antagonistic effects of enclomiphene over time. Additionally, some men report visual disturbances, mood changes, and elevated estradiol levels during treatment. These considerations have driven research interest toward enclomiphene as a purified alternative. A full analysis of clomid versus enclomiphene is covered in a dedicated comparison article. Forthcoming articles will also address clomid dosing protocols for men and clomid side effects in detail.

Shop Clomid at Elite Bio Supply

Enclomiphene Citrate: The Purified Isomer

Enclomiphene citrate is the isolated trans-isomer of clomiphene. By removing the zuclomiphene component, enclomiphene offers pure estrogen receptor antagonism at the hypothalamus without the confounding weak agonist activity of its counterpart. This pharmacological refinement was the basis for the development of Androxal, an investigational drug that underwent multiple Phase III clinical trials for the treatment of secondary hypogonadism in men.

The Androxal clinical programme produced notable data. Wiehle et al. (2014) published results demonstrating that enclomiphene citrate effectively stimulated endogenous testosterone production while preventing the oligospermia (reduced sperm count) associated with exogenous testosterone therapy. In these trials, enclomiphene raised total testosterone into the eugonadal range in a majority of subjects and maintained or improved semen parameters, a combination that exogenous testosterone fundamentally cannot achieve.

The FDA pathway for enclomiphene has been complex. Despite positive efficacy data, enclomiphene (as Androxal) received a Complete Response Letter from the FDA, citing concerns that were primarily related to study design and pharmacokinetic data rather than safety signals. As of 2026, enclomiphene citrate does not hold FDA approval for any indication, though it remains widely available through research chemical suppliers and compounding channels.

From a pharmacokinetic standpoint, enclomiphene has a substantially shorter half-life than the zuclomiphene isomer found in racemic clomiphene. This shorter half-life may offer advantages in terms of dose titration and washout if discontinuation is desired. Some researchers have noted that the absence of zuclomiphene accumulation may reduce the risk of estrogen-related side effects during prolonged administration.

The typical research dose range for enclomiphene is 12.5 to 25 mg daily. Head-to-head comparisons with racemic clomiphene suggest comparable testosterone elevation with potentially fewer estrogenic side effects, though the total body of evidence for enclomiphene is smaller than that for clomiphene citrate. Our enclomiphene FDA approval analysis and enclomiphene for bodybuilding articles examine these topics in greater detail.

Tamoxifen (Nolvadex): Estrogen Modulation Beyond Breast Cancer

Tamoxifen citrate, marketed as Nolvadex, is a SERM that has been in clinical use since the 1970s, primarily for the treatment and prevention of estrogen receptor-positive breast cancer. Its mechanism of action involves competitive binding to estrogen receptors, with antagonist activity predominating in breast tissue and the hypothalamus, and partial agonist activity in bone and the uterus.

In men, tamoxifen’s hypothalamic estrogen antagonism produces the same fundamental effect as clomiphene: increased GnRH pulsatility, elevated LH and FSH, and consequently higher endogenous testosterone production. Studies have demonstrated that tamoxifen at 20 mg daily can increase testosterone levels by 100 to 200 percent in hypogonadal men, with corresponding increases in gonadotropin levels (Shabsigh et al., 2005). The magnitude of testosterone elevation with tamoxifen appears broadly comparable to that achieved with clomiphene, though direct head-to-head randomized trials are limited.

One notable pharmacological distinction between tamoxifen and clomiphene relates to estrogen receptor specificity. Tamoxifen interacts with both estrogen receptor alpha (ER-alpha) and estrogen receptor beta (ER-beta), with tissue-dependent effects that differ from clomiphene’s receptor binding profile. These differences may account for the varying side effect profiles observed between the two compounds, though the clinical significance of these distinctions requires further study.

Tamoxifen has a well-characterized safety profile established through decades of oncological use. Hepatic effects, including rare cases of hepatotoxicity, have been documented primarily in the context of long-term, high-dose administration in cancer patients. Venous thromboembolism (VTE) risk is modestly elevated with tamoxifen use, consistent with its partial estrogen agonist activity in certain vascular tissues. Visual side effects are less commonly reported with tamoxifen than with clomiphene, which may influence compound selection in individuals sensitive to ocular changes.

Tamoxifen’s role in post cycle therapy is well established in the bodybuilding and performance enhancement literature, where it is commonly used alongside or as an alternative to clomiphene for hypothalamic-pituitary-testicular axis (HPTA) recovery. Our Tamoxifen guide examines the evidence for tamoxifen in male applications in comprehensive detail.

Raloxifene: Selective Benefits for Gynecomastia

Raloxifene hydrochloride, marketed as Evista, is a second-generation SERM that was developed primarily for the prevention and treatment of postmenopausal osteoporosis. Its tissue selectivity profile differs meaningfully from both clomiphene and tamoxifen, with estrogen antagonist activity in breast tissue, partial agonist activity in bone, and a neutral or mildly beneficial effect on lipid profiles.

In the context of male health, raloxifene has attracted attention primarily for its potential efficacy in the treatment and prevention of gynecomastia. Several studies have examined raloxifene for pubertal gynecomastia, with Lawrence et al. (2004) reporting that raloxifene at 60 mg daily produced a statistically significant reduction in breast tissue volume in adolescent boys compared to placebo. This finding has been extrapolated to adult male gynecomastia, though the evidence base in adult men is more limited and consists primarily of case series and retrospective analyses.

The mechanism underlying raloxifene’s anti-gynecomastia effect is straightforward. By blocking estrogen receptor activity in breast tissue, raloxifene prevents estradiol-mediated stimulation of mammary glandular proliferation. This tissue-specific antagonism occurs without necessarily affecting hypothalamic estrogen feedback to the same degree as clomiphene or tamoxifen, which means raloxifene’s testosterone-elevating effect is generally considered less potent than that of the other SERMs discussed in this guide.

Raloxifene’s bone-protective properties represent an additional consideration. As an estrogen agonist in bone tissue, raloxifene supports bone mineral density, which may be relevant for men with osteopenia or osteoporosis, conditions that are more prevalent in hypogonadal men than commonly recognized. The compound also demonstrates a favourable cardiovascular safety profile, with data suggesting neutral to mildly beneficial effects on LDL cholesterol.

The typical research dose for raloxifene in male applications ranges from 60 mg daily (the standard osteoporosis dose) to lower doses in protocols targeting gynecomastia prevention. A forthcoming raloxifene for gynecomastia article will examine the clinical evidence, dosing strategies, and comparative efficacy in detail.

SERM Comparison Table

SERM	Half-Life	Typical Male Research Dose	Primary Evidence in Men	Fertility Impact	Estrogen Effect on Bone	FDA Status (Male Use)
Clomiphene Citrate (Clomid)	5 to 7 days (zuclomiphene)	25 to 50 mg daily	Multiple studies in secondary hypogonadism, fertility preservation	Preserves or improves spermatogenesis	Partial agonist (mildly protective)	Off-label (approved for female anovulation)
Enclomiphene Citrate	10 to 12 hours	12.5 to 25 mg daily	Phase III trials (Androxal) in secondary hypogonadism	Preserves or improves spermatogenesis	Antagonist at hypothalamus; bone effects less characterized	Not FDA approved (CRL issued)
Tamoxifen (Nolvadex)	5 to 7 days	10 to 20 mg daily	Testosterone elevation in hypogonadal men, PCT recovery	Preserves spermatogenesis	Partial agonist (protective)	Off-label (approved for breast cancer)
Raloxifene (Evista)	27 to 32 hours	60 mg daily	Gynecomastia reduction, bone density	Minimal data; likely neutral	Agonist (protective)	Off-label (approved for osteoporosis)

SERMs vs TRT: Key Differences

The comparison between SERMs and testosterone replacement therapy is one of the most consequential clinical decisions in the management of male hypogonadism. Both approaches raise testosterone levels, but they do so through fundamentally different mechanisms with profoundly different downstream effects.

TRT delivers exogenous testosterone directly into the body, typically via injection, transdermal gel, or pellet implantation. This reliably elevates serum testosterone to the target range. However, the exogenous testosterone activates hypothalamic negative feedback, suppressing GnRH, LH, and FSH. The result is testicular suppression: reduced testicular volume, impaired spermatogenesis, and in many cases functional infertility that may persist for months after discontinuation. Kim et al. (2012) highlighted this concern as a primary reason to consider SERMs for hypogonadal men of reproductive age.

SERMs, by contrast, stimulate endogenous testosterone production through the body’s own hormonal cascade. LH and FSH levels increase rather than decrease. The testes remain fully engaged. Spermatogenesis is preserved or enhanced. This distinction makes SERMs the preferred approach in research contexts where fertility preservation is a priority.

However, the comparison is not one-sided. TRT generally achieves higher and more predictable testosterone levels than SERMs. Some men on SERM therapy report that while their laboratory values improve substantially, subjective symptom resolution (energy, libido, body composition) does not fully match what is achieved with TRT. One hypothesis is that SERM-mediated estradiol changes (since estradiol typically rises in parallel with testosterone during SERM therapy) may blunt some of the subjective benefits. Trost and Mulhall (2016) noted that challenges in testosterone measurement and data interpretation complicate direct comparisons between the two modalities.

Reversibility differs as well. SERM therapy, once discontinued, allows the HPG axis to return to its baseline state relatively quickly, particularly with shorter-acting compounds like enclomiphene. TRT discontinuation, particularly after prolonged use, may result in a protracted period of hypogonadism as the suppressed axis recovers, a process that can take months and may not fully normalize in all individuals.

Cost considerations also factor into the comparison. Generic clomiphene citrate and tamoxifen are significantly less expensive than most branded TRT formulations. For researchers and clinicians operating in cost-sensitive environments, SERMs may represent a more economically viable option for long-term hormonal modulation.

Post Cycle Therapy with SERMs

Post cycle therapy (PCT) refers to the protocol employed after the cessation of exogenous androgen use (such as anabolic steroids or testosterone) to facilitate recovery of endogenous hormonal function. During exogenous androgen administration, the HPG axis is suppressed. LH and FSH levels fall, the testes atrophy, and endogenous testosterone production ceases. Upon discontinuation, the body must restart this suppressed system, a process that can be slow and incomplete without pharmacological support.

SERMs are the cornerstone of most PCT protocols. By blocking hypothalamic estrogen receptors, SERMs accelerate the recovery of GnRH pulsatility, which in turn drives LH and FSH production and downstream testicular testosterone synthesis. The goal is to minimize the window of post-cycle hypogonadism, during which individuals may experience fatigue, muscle loss, mood disturbances, and sexual dysfunction.

The two SERMs most commonly employed in PCT are clomiphene citrate and tamoxifen. Some protocols use both compounds simultaneously, capitalizing on their complementary receptor binding profiles. A typical PCT protocol might involve tamoxifen at 20 mg daily combined with clomiphene at 50 mg daily for two to four weeks, followed by a tapering period. The specific protocol depends on the duration and intensity of the preceding androgen cycle, the compounds used, and individual recovery characteristics.

Enclomiphene is increasingly discussed as a PCT option due to its shorter half-life and absence of estrogenic zuclomiphene accumulation. However, the published evidence specifically examining enclomiphene in a PCT context is limited compared to the established data for clomiphene and tamoxifen.

Our Clomid PCT Protocol guide covers protocol design, timing considerations, and common pitfalls in detail.

Monitoring and Bloodwork

Appropriate laboratory monitoring is essential for any researcher or individual exploring SERM compounds. Baseline bloodwork establishes a reference point and helps identify pre-existing conditions that may influence compound selection or contraindicate SERM use altogether.

Baseline Panel (Before Starting)

A comprehensive baseline panel should include total testosterone, free testosterone (calculated or measured by equilibrium dialysis), estradiol (sensitive assay, LC-MS/MS preferred), LH, FSH, sex hormone-binding globulin (SHBG), complete blood count (CBC), comprehensive metabolic panel (CMP) including liver enzymes (AST, ALT), and lipid panel. Prolactin should also be assessed to rule out pituitary pathology as a cause of secondary hypogonadism.

Follow-Up Testing

Follow-up bloodwork is typically recommended at four to six weeks after initiating a SERM protocol, as this allows sufficient time for steady-state levels to be achieved and for the HPG axis response to stabilize. Key markers to track include total and free testosterone (to assess response magnitude), estradiol (which typically rises alongside testosterone during SERM therapy), LH and FSH (to confirm that the hypothalamic-pituitary response is intact), and liver enzymes (particularly with tamoxifen use).

Red Flags

Markers that warrant attention or protocol reassessment include estradiol levels rising disproportionately relative to testosterone, significantly elevated liver enzymes (greater than two times the upper limit of normal), polycythaemia (elevated haematocrit above 54 percent), and an inadequate testosterone response despite elevated LH (which may suggest primary testicular insufficiency).

A bloodwork guide for SERM users covering detailed reference ranges, testing frequency recommendations, and interpretation frameworks is planned for this series.

Safety and Side Effects

Each SERM carries a distinct side effect profile, and researchers should be familiar with compound-specific risks when evaluating these agents.

Clomiphene Citrate

The most notable side effect associated with clomiphene is visual disturbance, which may include blurred vision, floaters, photophobia, and in rare cases, persistent visual changes. These effects are thought to be related to zuclomiphene accumulation and its potential effects on retinal tissue. Visual symptoms generally resolve upon discontinuation but warrant immediate cessation of the compound. Other reported side effects include mood changes (irritability, emotional lability), headache, and elevated estradiol. The long half-life of zuclomiphene means that side effects may persist for days to weeks after the last dose.

Enclomiphene Citrate

The side effect profile of enclomiphene appears more favourable than racemic clomiphene in the available clinical trial data. Visual disturbances were reported at lower rates in Androxal trials compared to historical clomiphene data, consistent with the hypothesis that zuclomiphene drives many of the ocular side effects. Headache, nausea, and hot flushes have been reported. The shorter half-life facilitates faster resolution of any adverse effects upon discontinuation.

Tamoxifen

Tamoxifen’s long-term safety data, derived primarily from oncological use in women, includes a modestly elevated risk of venous thromboembolism and, in rare cases, hepatotoxicity. In men, the most commonly reported side effects at male-relevant doses (10 to 20 mg daily) include hot flushes, gastrointestinal discomfort, and headache. Tamoxifen’s partial estrogen agonist activity in bone is generally considered beneficial, but its agonist effects in other tissues (such as the endometrium in women) are less relevant in the male context. Long-term ocular effects (cataracts, retinal changes) have been reported in oncological populations but are uncommon at the lower doses and shorter durations typical of male research applications.

Raloxifene

Raloxifene is generally well tolerated. The primary safety concerns from the osteoporosis literature include an elevated VTE risk (comparable to tamoxifen) and leg cramps. Hot flushes are the most commonly reported side effect. Raloxifene does not appear to carry the hepatotoxicity risk associated with tamoxifen and does not cause visual disturbances. Its neutral endometrial profile (relevant in women) and bone-protective properties contribute to a favourable overall safety assessment.

A dedicated article on clomid side effects in men will provide an in-depth analysis of the most commonly studied SERM’s adverse effect profile.

Legal and Regulatory Status in Canada

The regulatory landscape for SERMs in Canada is governed by Health Canada and the Controlled Drugs and Substances Act (CDSA). SERMs are not classified as controlled substances in Canada. They are prescription medications, meaning they require a valid prescription for dispensation through licensed pharmacies.

Clomiphene citrate (Clomid) holds a Notice of Compliance from Health Canada for the treatment of ovulatory dysfunction in women. Its use in men for hypogonadism or fertility support is considered off-label. Tamoxifen (Nolvadex) is approved in Canada for the treatment of breast cancer. Raloxifene (Evista) holds Canadian approval for the prevention and treatment of postmenopausal osteoporosis. Enclomiphene citrate does not hold regulatory approval in Canada or the United States as of early 2026.

Research chemicals, including SERMs sold for investigational or research purposes, occupy a distinct regulatory category. These products are not intended for human consumption and are sold under the condition that purchasers accept responsibility for their intended use. Researchers should familiarize themselves with applicable federal and provincial regulations governing the acquisition and use of such compounds.

The legal framework in Canada does not criminalize the personal possession of SERMs, distinguishing them from anabolic steroids, which are Schedule IV substances under the CDSA. However, the importation, sale, and distribution of pharmaceutical products outside of licensed channels are subject to regulatory enforcement.

Frequently Asked Questions

What is the most commonly used SERM for men?

Clomiphene citrate (Clomid) is the most widely studied and most commonly used SERM for male applications. It has the largest evidence base for testosterone elevation and fertility preservation in hypogonadal men, with multiple clinical studies spanning over two decades of use.

Can SERMs replace TRT?

SERMs can serve as an alternative to TRT for certain populations, particularly men with secondary hypogonadism who wish to preserve fertility. However, SERMs generally produce more modest testosterone elevations than TRT, and subjective symptom improvement may not be equivalent. The decision between SERMs and TRT depends on individual clinical goals, fertility considerations, and response to therapy.

Do SERMs affect fertility?

Unlike TRT, which suppresses spermatogenesis, SERMs preserve and often enhance male fertility. By increasing FSH levels, SERMs support Sertoli cell function and sperm production. This is one of the primary advantages of SERM therapy for men of reproductive age (Kim et al., 2012).

What is the difference between clomiphene and enclomiphene?

Clomiphene citrate is a racemic mixture of two isomers: enclomiphene (estrogen antagonist) and zuclomiphene (weak estrogen agonist). Enclomiphene citrate is the isolated trans-isomer only. By removing zuclomiphene, enclomiphene provides pure estrogen antagonism with a shorter half-life and potentially fewer side effects. A detailed comparison is available in the clomid versus enclomiphene article.

How long does it take for SERMs to raise testosterone?

Most men experience measurable increases in LH and testosterone within one to two weeks of initiating SERM therapy. However, steady-state levels and full hormonal response typically require four to six weeks, which is why follow-up bloodwork is generally recommended at the six-week mark.

Are SERMs safe for long-term use in men?

Long-term safety data for SERMs in men is limited because most studies have examined relatively short treatment durations (three to twelve months). Tamoxifen has the longest safety record due to its decades of oncological use, though primarily in women. Potential long-term concerns include visual changes with clomiphene, hepatic effects with tamoxifen, and VTE risk with tamoxifen and raloxifene. Regular monitoring with bloodwork is recommended for any extended protocol.

Can SERMs be used for gynecomastia?

Raloxifene has the most direct evidence for gynecomastia treatment, with studies demonstrating breast tissue volume reduction in adolescent males. Tamoxifen has also been used for gynecomastia with documented efficacy. Clomiphene is less commonly used for this specific indication due to its mixed estrogen agonist and antagonist profile at breast tissue.

What bloodwork should be done before starting a SERM?

A baseline panel should include total testosterone, free testosterone, estradiol (sensitive assay), LH, FSH, SHBG, prolactin, CBC, CMP with liver enzymes, and lipid panel. This establishes baseline values and helps rule out conditions that may contraindicate SERM use or require alternative management.

Do SERMs raise estrogen levels?

SERMs do not directly raise estrogen levels. However, by increasing testosterone production, they indirectly lead to higher estradiol levels, since testosterone is partially converted to estradiol by aromatase. This is an important distinction from aromatase inhibitors, which directly suppress estrogen production. The estradiol increase during SERM therapy is proportional to the testosterone increase and generally remains within physiological ranges.

Are SERMs legal in Canada?

SERMs are not controlled substances in Canada. They are prescription medications that can be legally prescribed by physicians for off-label use. Research chemical suppliers operate under separate regulatory frameworks. Personal possession of SERMs is not criminalized under the Controlled Drugs and Substances Act, unlike anabolic steroids which are Schedule IV substances.

References

1. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573-578. doi:10.1111/j.1464-410X.2011.10702.x
2. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156-165. doi:10.1038/sj.ijir.3900981
3. Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in men of reproductive age. Fertil Steril. 2013;99(3):718-724. doi:10.1016/j.fertnstert.2012.10.052
4. Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. doi:10.1016/j.fertnstert.2014.06.004
5. Trost LW, Mulhall JP. Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials. J Sex Med. 2016;13(7):1029-1046. doi:10.1016/j.jsxm.2016.04.068
6. Shabsigh A, Kang Y, Shabsigh R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med. 2005;2(5):716-721. doi:10.1111/j.1743-6109.2005.00075.x
7. Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7(1 Pt 1):269-276. doi:10.1111/j.1743-6109.2009.01454.x
8. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145(1):71-76. doi:10.1016/j.jpeds.2004.03.057
9. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012;110(10):1524-1528. doi:10.1111/j.1464-410X.2012.10968.x
10. Helo S, Ellen J, Engel J, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12(8):1761-1769. doi:10.1111/jsm.12944
11. Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Howards S. Clomiphene citrate for the treatment of hypogonadism. Sex Med Rev. 2019;7(2):272-276. doi:10.1016/j.sxmr.2018.10.001
12. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. 2014;192(3):875-879. doi:10.1016/j.juro.2014.03.089
13. Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48-51. doi:10.1016/j.fertnstert.2012.04.005
14. Ring J, Lwin A, Köhler T. Current medical management of endocrine-related male infertility. Asian J Androl. 2016;18(3):357-363. doi:10.4103/1008-682X.179252
15. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
16. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril. 2003;79(1):203-205. doi:10.1016/S0015-0282(02)04550-8

Elite Bio Supply ships pharmaceutical-grade SERMs to researchers across Canada. Available with domestic shipping to Toronto, Vancouver, Montreal, Calgary, Edmonton, Ottawa, and all Canadian cities via Canada Post.